News & Analysis as of

Emerging Growth Companies Initial Public Offering (IPO) Life Sciences

Emerging Growth Companies (EGC) are companies with total yearly gross revenues of under $1 billion for the most recently completed fiscal year.  
Woodruff Sawyer

[Ongoing Program] Risk Management for Your Life Sciences Company: Webinar 3 - International Clinical Trials Country Requirements-...

Woodruff Sawyer on

From lab to commercialization: Navigate the evolving risks of life science companies - Life science companies face rapidly evolving risks—from navigating insurance needs during early funding stages to understanding...more

Woodruff Sawyer

[Ongoing Program] Risk Management for Your Life Sciences Company: Webinar 2 - AI In Real Life (Science): Exploring Real World...

Woodruff Sawyer on

From lab to commercialization: Navigate the evolving risks of life science companies - Life science companies face rapidly evolving risks—from navigating insurance needs during early funding stages to understanding...more

Woodruff Sawyer

[Ongoing Program] Risk Management for Your Life Sciences Company: Webinar 1 - Navigating Risk from Lab to IPO: A Guide to...

Woodruff Sawyer on

From lab to commercialization: Navigate the evolving risks of life science companies - Life science companies face rapidly evolving risks—from navigating insurance needs during early funding stages to understanding...more

Fenwick & West LLP

Key Takeaways: Navigating the Life Sciences IPO Journey

Fenwick & West LLP on

The journey to becoming a public company requires strategic planning and thoughtful coordination. While the IPO process typically spans six months or more, laying the groundwork should begin much earlier to ensure a smooth...more

Wilson Sonsini Goodrich & Rosati

2023 Technology and Life Sciences IPO Report

Market volatility, high interest rates, and ongoing geopolitical conflict continue to influence low levels of IPO activity in the U.S. capital markets. The trend is observed across all sectors, resulting in IPO levels similar...more

Allen Matkins

Life Sciences Real Estate Update 10.16.23

Allen Matkins on

Boston, the San Francisco Bay Area, and San Diego are once again the top markets for life sciences commercial real estate in the U.S., with plenty of opportunities for growth as biotech readies for a comeback, according to a...more

Procopio, Cory, Hargreaves & Savitch LLP

Navigating a Tough Market: Insights and Strategies for Emerging Public Companies Raising Capital and Avoiding Delisting

After a market flush with cash and deal flow from 2020 through the first half of 2022, in the last six to twelve months the markets have been particularly tight. Particularly impacted in this turbulent market have been small...more

Fenwick & West LLP

Navigating Uncertain Times: IPO Insights for Late-Stage Technology and Life Sciences Companies - 2023

Fenwick & West LLP on

After 2022’s challenging capital markets environment, leaders in the technology and life sciences industries have set their sights on 2023 and beyond—evaluating the private fundraising market, looking for ways to extend their...more

Wilson Sonsini Goodrich & Rosati

2021 Mid-Year Technology and Life Sciences IPO Report

Wilson Sonsini Goodrich & Rosati’s 2021 Mid-Year Technology and Life Sciences IPO Report presents analyses related to the pricing of 123 initial public offerings completed by U.S.-based technology and life sciences companies...more

Goodwin

UK Listings Review: Do New Recommendations Change The Game For Tech And Life Sciences Companies?

Goodwin on

The review of the UK Listing Rules was launched by HM Treasury (the Treasury) late last year and has made a number of wide-ranging recommendations of relevance for our tech and life sciences clients who have ambitions to go...more

Wilson Sonsini Goodrich & Rosati

2020 Technology and Life Sciences IPO Report

Wilson Sonsini’s 2020 Technology and Life Sciences IPO Report presents analysis and data related to the pricing of 123 initial public offerings completed by U.S.-based technology and life sciences companies between January 1...more

Fenwick & West LLP

Key Metrics for U.S. Technology and Life Sciences IPO Survey – 2020 First Half

Fenwick & West LLP on

Key Metrics for Recent Technology and Life Sciences Initial Public Offerings - Following a volatile spring 2020 due to the rapid global spread of the novel coronavirus, the capital markets, including IPOs, appear to be...more

Fenwick & West LLP

Key Metrics for Technology and Life Sciences Initial Public Offerings - 2019 Full Year

Fenwick & West LLP on

Survey Results - Life Sciences and Technology IPOs Stay Strong in Second Half Despite Bumps - U.S. initial public offerings notched another robust year in 2019 despite bouts of volatility, a number of high-profile...more

Wilson Sonsini Goodrich & Rosati

2019 Technology and Life Sciences IPO Report

Wilson Sonsini Goodrich & Rosati’s 2019 Technology and Life Sciences IPO Report presents analysis related to the closing of 87 initial public offerings completed by U.S.-based technology and life sciences issuers between...more

Mayer Brown Free Writings + Perspectives

Healthcare and Tech Remain Strong During Slow IPO Market

US IPO volume has declined by almost a quarter year-over-year, according to EY’s recent Global IPO trends report.  To date, $44.5 billion in proceeds have been raised in 127 IPOs, 23% less than at the end of Q3 2018. The...more

Arnall Golden Gregory LLP

[Webinar] Money, Money, Money: Raising Capital and Exit Transactions for Life Sciences Companies - October 3rd, 12:00 pm ET

Access to capital is critical for life sciences companies. Securing funding can be a lengthy and complex process compounded by the need to plan for various exit transaction scenarios. Register now for this one-hour,...more

Wilson Sonsini Goodrich & Rosati

2019 Mid-Year Technology and Life Sciences IPO Report

Wilson Sonsini Goodrich & Rosati’s 2019 Mid-Year Technology and Life Sciences IPO Report presents analysis related to the pricing of 49 initial public offerings completed by U.S.-based technology and life sciences issuers...more

Fenwick & West Life Sciences Group

Life Sciences IPOs Haven’t Slowed in 2019

In our 2018 year-end review of life sciences and tech IPOs, we noted that life sciences offerings totaled 67 raising an average of $133 million while there were 45 technology deals raising an average of more than $380...more

Fenwick & West Life Sciences Group

Which Way to the Exits for Biotech?

With 58 U.S. biopharma IPOs in 2018, the biotech industry entered the new year with confidence. By all appearances, the longest and largest biotech IPO window in history was not going to close anytime soon. ...more

Fenwick & West LLP

Key Metrics for Technology and Life Sciences Initial Public Offerings - 2018 Full Year

Fenwick & West LLP on

Survey Results - Life Sciences and Tech IPOs Continued Hot Streak in Second Half - The life sciences and technology IPO markets continued their strong performance in the second half of 2018, notwithstanding significant...more

Orrick, Herrington & Sutcliffe LLP

Profiles in Innovation: Twist Bioscience’s Co-Founder Navigates Company from Start-up to Public Company

As a pioneer in DNA synthesis with several patents to her name, Dr. Emily Leproust could have enjoyed a distinguished career without ever leaving the lab. Instead she founded (and just took public) a company that promises to...more

Troutman Pepper Locke

To IPO, Or Not to IPO, That Is the Question - How to prepare for and execute a successful public offering

Troutman Pepper Locke on

More than ever, life sciences companies are going public to raise capital for future growth. In fact, U.S. equity financing in life sciences skyrocketed to a record $7 billion in 2018—a 69 percent jump over the year before. ...more

Wilson Sonsini Goodrich & Rosati

2018 Technology and Life Sciences IPO Report

Wilson Sonsini Goodrich & Rosati’s 2018 Technology and Life Sciences IPO Report presents data related to the pricing of 93 IPOs completed by U.S.-based technology and life sciences issuers between January 1 and December 10,...more

Wilson Sonsini Goodrich & Rosati

2018 Mid-Year Technology and Life Sciences IPO Report

Wilson Sonsini Goodrich & Rosati’s 2018 Mid-Year Technology and Life Sciences IPO Report presents analysis related to the pricing of 50 initial public offerings completed by U.S.-based technology and life sciences issuers...more

Fenwick & West LLP

Technology and Life Sciences IPO Survey – 2017, Full Year

Fenwick & West LLP on

This report analyzes key aspects of initial public offerings (IPOs) for technology and life sciences companies that went public in 2017, with emphasis on data from the second half of the year. Our IPO Survey was developed for...more

46 Results
 / 
View per page
Page: of 2

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide